Boothbay Fund Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Boothbay Fund Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-14,294	Closed	-$1.81M	–	2713
2022 Q2	$1.81M	Buy	14,294 +8,164	+133%	+$938K	0.05%	584
2022 Q1	$777K	Buy	+6,130	New	+$690K	0.02%	1058
2020 Q1	–	Sell	-3,000	Closed	-$226K	–	1123
2019 Q4	$226K	Buy	+3,000	New	+$131K	0.02%	669

Other funds holding KRTX

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Boothbay Fund Management's KRTX Position: Q3 2022 in Review

Boothbay Fund Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2022, closing a stake of 14,294 shares — an estimated $1.81M sold.

Boothbay Fund Management first reported a position in KRTX in Q4 2019 and held it in 3 quarters. The position peaked at $1.81M in Q2 2022. 257 funds tracked by Wall St. Rank hold KRTX as of Q3 2022.

Boothbay Fund Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Boothbay Fund Management sold 14,294 Karuna Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1.81M.
Boothbay Fund Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 3 quarters.
Boothbay Fund Management's Karuna Therapeutics, Inc. Common Stock position peaked at $1.81M in Q2 2022.
257 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.